Elan Corporation PLC has appointed Hans Peter Hasler as chief operating officer of the biotechnology company, saying Thursday that he would help increase the company’s long-term growth.
Hasler is currently a director of the company. He will assume his new role on Oct. 1 and retire from the board.
Hasler was appointed a director of Elan in September 2011. He is currently the chairman of investment firm HBM Bioventures AG and principal of biotechnology consulting business HPH Management GmbH. Hasler worked with drug developer Biogen Idec Inc. in a number of leadership roles from 2001 to 2009, most recently as its chief operating officer.
Elan, based in Dublin, is a neuroscience-focused biotechnology company. It announced last month that it plans to split into two public companies.
